Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Blood tests could reveal how septic shock patients are responding

NCT ID NCT07401329

Knowledge-focused Sponsor: Pandit Bhagwat Dayal Sharma, PGIMS, Rohtak Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two blood markers—nCD64 and mHLA-DR—in 76 adults with septic shock, a life-threatening infection that can cause organ failure. Doctors measured these markers on day 1 and day 8 to see how the immune system changed over time. The goal was to learn whether these markers can help predict which patients are more likely to survive.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

76 people

The number who actually took part.

Started

Jan 2019

Finished

Dec 2019

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

All patients aged over 18 years with a diagnosis of septic shock

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: Patients were eligible if they met all of the following: * Age ≥ 18 years. * Diagnosis of septic shock according to prevailing Sepsis-3 criteria at the time of study. * Admission to the medical ICU of the tertiary care teaching hospital. * Written informed consent obtained from patient or next of kin. Exclusion Criteria: Patients were excluded if they met any of the following: * Pregnant females. * Active malignancy (any known cancer diagnosis). * Severe chronic liver disease. * Chronic kidney disease requiring maintenance hemodialysis. * Immunocompromised state, including: * HIV/AIDS. * Long-term corticosteroid therapy. * Other immunosuppressive conditions. * Prior immunomodulatory treatment before onset of sepsis (e.g., biologics, GM-CSF, interferons). * Non-bacterial sepsis, including: * Viral sepsis. * Fungal sepsis. * Tubercular sepsis.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sepsis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

infectious disease with sepsis Sepsis toxic shock syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sepsis Septic shock

Contacts and locations

Locations

  • Pandit Bhagwat Dayal Sharma Postgraduate Institute of Medical Sciences

    Rohtak, Haryana, 124001, India

More trials for these conditions

Other studies related to the condition(s) this trial covers.